• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Equitable Access to Molecular Testing and Treatment Prioritization

Opinion
Video

Panelists discuss how to overcome barriers to comprehensive molecular testing and how to prioritize treatment when ALK+ non–small cell lung cancer (NSCLC) coexists with other actionable biomarkers.

Molecular Testing and Biomarker Considerations

Key Themes:

  • Barriers to equitable access for comprehensive molecular testing
  • Strategies to overcome testing barriers
  • Treatment prioritization when ALK+ status coexists with other actionable biomarkers

Notable Insights:

  • Dr Dietrich identified barriers to comprehensive molecular testing including NGS
  • Grizzard offered suggestions for clinicians to overcome testing barriers

Dr Lovly addressed treatment prioritization in patients with both ALK+ status and other biomarkers (eg, PD-L1 >1%)

Related Videos
Samir Shah, MD, MMM, FACR
1 expert in this video
5 experts are featured in this series
1 expert in this video
5 experts are featured in this series
Dr Brian Slomovitz
Related Content
© 2025 MJH Life Sciences
AJMC®
All rights reserved.